-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117

Benzinga·11/07/2026 00:51:24
Listen to the news
Leerink Partners analyst David Risinger downgrades Halozyme Therapeutics (NASDAQ:HALO) from Outperform to Market Perform and raises the price target from $110 to $117.